<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02209337</url>
  </required_header>
  <id_info>
    <org_study_id>CD-14-005</org_study_id>
    <nct_id>NCT02209337</nct_id>
  </id_info>
  <brief_title>Demonstrate the Safety and Preformance of the SRS Device for the Treatment of Pelvic Organ Prolapse</brief_title>
  <official_title>Demonstrate the Safety and Preformance of the SRS Device for the Treatment of Pelvic Organ Prolapse</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lyra Medical Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lyra Medical Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective, single arm, pre-market, multi-center clinical study to evaluate the safety and
      performance of the SRS (Lyra Medical) vaginal mesh in POP patients
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">September 2014</start_date>
  <completion_date type="Anticipated">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>No device related serious adverse events</measure>
    <time_frame>up to 12 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Minimal rate of device or procedure adverse events (intra and post operative Minimal rate of device or procedure adverse events (intra and post operative complications)</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in POP-Q: points Aa and Ba</measure>
    <time_frame>up to 12 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in POP-Q point C</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Achieving normal urinary function</measure>
    <time_frame>up to 12 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Anterior Vaginal Wall Prolapse</condition>
  <condition>Vaginal Apex/Uterine Prolapse</condition>
  <arm_group>
    <arm_group_label>SRS-I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Implantation of SRS-I</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SRS</intervention_name>
    <arm_group_label>SRS-I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patient has signed the informed consent form and is willing to participate in the
             clinical study and data collection.

          2. Patient age is between 18 and 75 years old

          3. POP-Q: Aa and/or Ba is at least -1

        Exclusion Criteria:

          1. Patient is pregnant or breastfeeding

          2. Patient suffering from active infection (on antibiotic therapy)

          3. Patient planning vaginal delivery

          4. Patient had Previous vaginal mesh surgery

          5. Patient is in high risk for surgery (evidence of clinically significant
             cardiovascular, renal, hepatic or respiratory diseases).

          6. Any condition that in the judgment of the investigators would interfere with the
             subject's ability to provide informed consent, comply with study instructions, place
             the subject at increased risk, or which might confound interpretation of study
             results.

          7. Malignancy .

          8. Known hypersensitivity to PEEK and polypropylene materials.

          9. Participation in another investigational trial that has not completed the primary
             endpoint or interferes with study participation.

         10. Tendency for hyper-scaring reaction

         11. Diagnosed with mental or emotional disturbance.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gil Levi, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayanei HaYeshua Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Szeged</name>
      <address>
        <city>Szeged</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayanei HaYeshua Medical Center</name>
      <address>
        <city>Bnei Brak</city>
        <zip>51544</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asaf HaRofeh Medical Center</name>
      <address>
        <city>Ztrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hungary</country>
    <country>Israel</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 3, 2014</study_first_submitted>
  <study_first_submitted_qc>August 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 5, 2014</study_first_posted>
  <last_update_submitted>June 19, 2017</last_update_submitted>
  <last_update_submitted_qc>June 19, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prolapse</mesh_term>
    <mesh_term>Pelvic Organ Prolapse</mesh_term>
    <mesh_term>Uterine Prolapse</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

